Results for
"[search-keyword]"
Sponsor content
339 result(s) found, displaying 41 to 50
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Designation or determinationPriority review
-
Designation or determinationOrphan drug
-
Australian Public Assessment Report (AusPAR)WELIREG (belzutifan) is indicated for treatment of patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system haemangioblastomas, or pancreatic neuroendocrine tumours, not requiring immediate surgery.
-
Australian Public Assessment Report (AusPAR)Vaxneuvance, a vaccine, has been approved for the prevention of pneumococcal disease caused by Streptococcus pneumoniae.
-
Australian Public Assessment Report (AusPAR)AusPAR for Gardasil 9 (HPV 9-valent vaccine, recombinant) for prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions, and infection caused by HPV in males.
-
Australian Public Assessment Report (AusPAR)Keytruda (pembrolizumab) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumours who are ineligible for or have elected not to undergo cystectomy.
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd